Skip to content

Study of a Strategy to Prevent Oversedation in Intensive Care Patients Under Mechanical Ventilation

Prevention of Oversedation in Intensive Care Patients Under Mechanical Ventilation : the AWARE Multicentric Randomized Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01617265
Acronym
AWARE
Enrollment
1180
Registered
2012-06-12
Start date
2012-06-30
Completion date
2015-06-30
Last updated
2015-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ICU Patients Requiring Invasive Mechanical Ventilation

Keywords

intensive care, mechanical ventilation, sedatives, morphinics, oversedation, mortality, midazolam, propofol, pain, agitation

Brief summary

The purpose of the present study is to determine whether administration of sedation according to a strategy including a bundle of measures to prevent oversedation is associated with a reduction in mortality of intensive care unit patients requiring mechanical ventilation, compared to administration of sedation according to usual practices.

Detailed description

In intensive care unit (ICU) patients receiving mechanical ventilation (MV), potent hypnotics and morphinics are frequently administered to increase synchrony with the ventilator, control agitation and decrease discomfort and pain due to the tracheal tube, bed ridding, painful condition and diagnostic or therapeutic procedures. However, administration sedatives or morphinics is often excessive and may result in deep and prolonged alteration of consciousness, delayed weaning from MV and prolonged MV. and exposes the patient to a higher risk of ventilator-associated pneumonia, ICU delirium and neuromuscular weakness at awakening. The present randomized multicenter study will compare the day-90 mortality of a group of patients receiving conventional sedation to the mortality of a group of patients receiving sedation administered according to an algorithm aimed to prevent oversedation to the mortality. The algorithm is built on a graduate therapeutic response to increasingly intense symptoms of discomfort, pain, ventilator dyssynchrony and agitation, and includes the use of analgesics, non hypnotic benzodiazepines, neuroleptics, repeated intravenous (IV) boluses of hypnotics and short duration (6 hours) IV hypnotic infusions.

Interventions

PROCEDUREClinical Procedure to Prevent Oversedation

Sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated IV hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.

PROCEDUREUsual sedation practice

Sedation and analgesia will be administered according to the usual practices in each participating center.

Sponsors

University Hospital, Tours
CollaboratorOTHER
French Society for Intensive Care
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 and older * Admission to ICU with expected mechanical ventilation duration \> 48 hrs * Mechanical ventilation in ICU for less than 12 hours * Information provided to the patient or proxy

Exclusion criteria

* ICU Admission after cardiac arrest * Acute or chronic neuromuscular disease * Tracheotomy on ICU admission * Acute cerebral injury with intracranial hypertension requiring continuous IV sedation with or without neuromuscular blockade * Status epilepticus * Treatment withdrawal decision * Pregnancy, breast feeding * Concurrent participation in another interventional study requiring a change in usual practice of sedation or mechanical ventilation

Design outcomes

Primary

MeasureTime frame
Day-90 mortalityMortality at Day 90 after randomization

Secondary

MeasureTime frameDescription
Hospital mortalityat hospital discharge, up to day 90
1-yr mortalityat 1 yr
Mechanical ventilation durationFrom onset of mechanical ventilation to day 28
Days alive with no mechanical ventilationFrom ICU admission up to day 28
Occurence of ventilator-associated pneumoniaDuring mechanical ventilation duration, up to day 28
Use of non-invasive ventilation after extubationFrom extubation to ICU discharge up to day 28
Mortality at Day 28at day 28
ICU confusionFrom Day 1 to 7, and at day 14, 21 and 28Number of patients alive, awaken, and free of ICU-delirium assessed on the CAM-ICU
Proximal muscle weaknessfrom day 1 to 7, and at day 14, 21 and 28Number of patients alive, awaken, cooperative and free of proximal muscle weakness
Functional, cognitive and psychological statusAt day 90 and 1 yearFunctional status (measured on the Barthel scale), depression (measured on the Hospital Anxiety & Depression Scale), Posttraumatic stress disorder (measured on the Impact of Event Scale), Quality of Life (measured on the SF-36) and patient living location
Time to weaning onsetTime from mechancial ventilation initiation to first spontaneous breathing trial, up to day 28
Number of patients requiring tracheotomyDuring ICU stay, up to day 28
First sitting in chairDuring ICU stay, up to day 28
Duration of ICU stayFrom ICU admission to ICU discharge or death in ICU, up to day 90

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026